Preventive effect of intestinal bacteria on non-B non-C liver carcinogenesis.

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K17471
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: Yokohama City University
• Principal Investigator: KESSOKU Takaomi 横浜市立大学, 附属病院, 助教 (30738620)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 肝がん / フェカリバクテリウム / 予防 / 腸管バリア

Outline of Final Research Achievements

Because we have been able to create liver cancer models and administer Fecalibacterium as planned, and have obtained research results that meet our hypothesis.In FY2020, we analyzed genes, proteins, and immune cells in the background liver and colonic epithelium within liver tumors and found that the increase in regulatory T cells by Fecalibacterium contributes to intestinal permeability.We found that the increase of regulatory T cells by Focalibacterium contributes to intestinal permeability. In addition, we conducted a corroborative experiment using the DSS enteritis model to determine whether liver tumor growth was mediated by intestinal permeability, and found that liver tumors increased under DSS treatment.It is thought that the increase in intestinal permeability contributes to the increase in liver tumors.

Free Research Field

非アルコール性脂肪肝疾患

Academic Significance and Societal Importance of the Research Achievements

フェカリバクテリウムが、非B非C肝がん発癌の予防をできる可能性があり、腸内細菌を用いた治療開発が望まれる。